Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Conditions
Interventions
Seladelpar
Placebo to match Seladelpar
Locations
10
United States
Sutter Pacific Medical Foundation - California Pacific Medical Center
San Francisco, California, United States
University of Colorado Denver and Hospital
Aurora, Colorado, United States
Schiff Center for Liver Diseases/University of Miami
Miami, Florida, United States
Piedmont Atlanta Hospital
Atlanta, Georgia, United States
Henry Ford Health System
Novi, Michigan, United States
New York University
New York, New York, United States
Start Date
November 12, 2019
Primary Completion Date
January 9, 2020
Completion Date
January 9, 2020
Last Updated
January 16, 2025
NCT04753996
NCT05750498
NCT05295680
NCT02137668
NCT05896137
NCT05740358
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions